Ipseiz Natacha, Scholtysek Carina, Culemann Stephan, Krönke Gerhard
Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nürnberg, Erlangen, Germany; Nikolaus Fiebiger Center of Molecular Medicine, University of Erlangen-Nürnberg, Erlangen, Germany.
Swiss Med Wkly. 2014 Dec 4;144:w14055. doi: 10.4414/smw.2014.14055. eCollection 2014.
Adopted orphan nuclear receptors, such as peroxisome proliferator-activated receptors (PPARs) and liver X receptors (LXRs), have emerged as key regulators of inflammation and immunity and likewise control skeletal homeostasis. These properties render them attractive targets for the therapy of various inflammatory and autoimmune diseases affecting the musculoskeletal system. This review summarises the current knowledge on the role of these families of receptors during innate and adaptive immunity as well as during the control of bone turnover and discuss the potential use of targeting these molecules during the treatment of chronic diseases such as osteoarthritis, rheumatoid arthritis and osteoporosis.
诸如过氧化物酶体增殖物激活受体(PPARs)和肝脏X受体(LXRs)等被采用的孤儿核受体,已成为炎症和免疫的关键调节因子,同样也控制骨骼稳态。这些特性使它们成为治疗影响肌肉骨骼系统的各种炎症和自身免疫性疾病的有吸引力的靶点。本综述总结了目前关于这些受体家族在先天性和适应性免疫以及骨转换控制过程中的作用的知识,并讨论了在治疗骨关节炎、类风湿性关节炎和骨质疏松症等慢性疾病时靶向这些分子的潜在用途。